

02-24-2006

U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark Office

REC



103195374

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)/Execution Date(s):

Novartis Finance Corporation

Execution Date(s) 3/1/2004

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Government Interest Assignment
☐ Executive Order 9424, Confirmatory License
☐ Other _____

2. Name and address of receiving party(ies)

Name: Syngenta Investment Corporation

Internal Address: _____

Street Address: 2200 Concord Pike

City: Wilmington

State: Delaware

Country: United States of America Zip: 19803

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application or patent number(s):

A. Patent Application No.(s)

☐ This document is being filed together with a new application.

B. Patent No.(s)

5,866,780

Additional numbers attached? ☐ Yes ☒ No

5. Name and address to whom correspondence concerning document should be mailed:

Name: Larry W. Stults

Internal Address: Syngenta Biotechnology, Inc.

Street Address: 3054 Cornwallis Road

City: Research Triangle Park

State: NC Zip: 27709

Phone Number: 919-765-5117

Fax Number: 919-541-8689

Email Address: edouard.lebel@syngenta.com

6. Total number of applications and patents involved:

1

7. Total fee (37 CFR 1.21(h) & 3.41) \$ 40.00

- ☒ Authorized to be charged by credit card
☐ Authorized to be charged to deposit account
☒ Enclosed
☐ None required (government interest not affecting title)

8. Payment Information

a. Credit Card Last 4 Numbers 8991
Expiration Date 4/06

b. Deposit Account Number _____

Authorized User Name 82/23/2006 L. W. LEBEL 00000034 5866780

81 EC-A021

48.00 0

9. Signature:

Edouard G. Lebel
Signature

2/16/2006
Date

Edouard G. Lebel, Ph.D., Reg. No. 43,742

Name of Person Signing

Total number of pages including cover sheet, attachments, and documents:

4

Documents to be recorded (including cover sheet) should be faxed to (703) 306-5995, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

PATENT
REEL: 017586 FRAME: 0322

ASSIGNMENT

Whereas, Novartis Finance Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, is the assignee and legal owner of the entire right, title and interest in each of the United States patents listed in Appendix B; and


Whereas, in accordance with a resolution of its Board of Directors made on October 31, 2000, Novartis Finance Corporation wishes to assign its entire interest in each of the United States patents listed in Appendix B and in certain related United States patents and patent applications to Syngenta Investment Corporation, 2200 Concord Pike, Wilmington, DE 19803, a corporation of Delaware, and said Syngenta Investment Corporation wishes to acquire Novartis Finance Corporation's interest in said patents and patent applications.

Now, therefore, Novartis Finance Corporation hereby assigns to Syngenta Investment Corporation and its successors and assigns its entire right, title and interest in (1) (a) each of the three hundred thirty-five (335) United States patents listed in Appendix B, (b) any and all applications for reissues of said patents, (c) any and all reissues of said patents that may be issued and/or granted, (d) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (e) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents) and (2) (a) any and all United States patent applications, whether pending or abandoned, that are continuations and divisions (including further continuations and divisions such as, but not limited to, continuations and divisions of continuations) of the applications which issued as the patents listed in Appendix B, (b) any and all United States patents that may have been or, in the future, that may be issued and/or granted on all of said applications, (c) any and all applications for reissues of said patents, (d) any and all reissues of said patents that may be issued and/or granted, (e) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (f) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), including, in the case of all patents (including reissue patents) within the scopes of (1) and (2), the right to sue, and to obtain damages, for past infringement, said right, title and interest conveyed herein by Novartis Finance Corporation to Syngenta Investment Corporation constituting the entire right, title and interest in said patents (including reissue patents), applications, extensions and reexamination certificates.

In witness whereof, Novartis Finance Corporation has caused this Assignment to be signed by its duly authorized corporate officer.

Signed this 1st day of March 2004.

Novartis Finance Corporation



Wayne P. Merkelson
Vice-President

Appendix B

4,600,428	4,886,887	5,120,741	5,430,188
4,601,745	4,888,348	5,135,927	5,436,248
4,602,936	4,897,109	5,153,200	5,439,912
4,603,211	4,897,396	5,166,153	5,446,154
4,605,656	4,897,424	5,166,430	5,447,935
4,608,372	4,900,827	5,169,951	5,447,945
4,612,037	4,902,340	5,175,293	5,451,595
4,612,395	4,904,778	5,179,094	5,457,276
4,618,360	4,908,467	5,183,492	5,466,785
4,623,382	4,914,098	5,190,928	5,477,002
4,629,810	4,918,088	5,194,628	5,478,958
4,632,695	4,918,230	5,204,100	5,481,013
4,671,819	4,919,704	5,209,771	5,484,918
4,674,229	4,919,935	5,217,871	5,489,695
4,681,619	4,921,980	5,232,898	5,493,032
4,686,294	4,925,840	5,237,084	5,496,848
4,692,524	4,925,842	5,245,040	5,506,099
4,693,741	4,925,876	5,250,556	5,508,184
4,693,745	4,931,439	5,250,557	5,508,402
4,705,800	4,931,560	5,250,559	5,514,795
4,707,182	4,931,581	5,254,739	5,514,816
4,709,092	4,935,051	5,262,386	5,519,026
4,727,186	4,938,797	5,266,554	5,519,125
4,729,190	4,939,257	5,266,585	5,521,153
4,753,954	4,944,790	5,274,100	5,521,195
4,758,667	4,948,798	5,276,186	5,523,311
4,759,793	4,952,726	5,280,041	5,527,760
4,766,253	4,958,030	5,281,718	5,527,917
4,780,125	4,959,096	5,286,709	5,530,195
4,780,551	4,962,126	5,296,449	5,536,726
4,798,688	4,968,344	5,302,605	5,536,900
4,810,724	4,978,383	5,302,607	5,538,979
4,812,164	4,989,741	5,310,721	5,541,148
4,831,148	4,992,434	5,322,853	5,541,310
4,833,255	4,996,325	5,324,842	5,545,630
4,847,258	4,997,941	5,332,717	5,552,368
4,849,007	4,997,967	5,350,689	5,554,619
4,849,009	5,002,604	5,373,013	5,556,828
4,849,219	5,002,606	5,384,321	5,558,997
4,851,028	5,023,259	5,384,403	5,559,034
4,851,031	5,023,333	5,384,416	5,561,230
4,853,396	5,041,603	5,397,697	5,567,705
4,854,963	5,049,571	5,399,545	5,583,249
4,857,100	5,063,236	5,403,814	5,585,238
4,859,229	5,075,316	5,403,844	5,585,519
4,861,787	5,075,443	5,407,934	5,595,733
4,866,079	5,077,311	5,409,823	5,596,131
4,870,184	5,082,860	5,412,107	5,597,779
4,872,902	5,102,445	5,420,301	5,597,840
4,881,964	5,104,440	5,430,034	5,599,771
4,881,986	5,112,849	5,430,035	5,599,828

Appendix B

5,601,847	5,731,266	5,925,367
5,606,057	5,731,267	5,929,102
5,610,042	5,731,500	5,942,662
5,610,044	5,731,501	5,945,437
5,612,288	5,731,502	5,955,274
5,614,395	5,731,506	5,955,362
5,625,071	5,758,766	5,958,835
5,625,136	5,759,561	5,981,582
5,627,188	5,763,481	5,990,383
5,631,007	5,766,900	6,017,850
5,637,763	5,767,369	6,017,851
5,639,949	5,770,450	6,018,105
5,641,666	5,770,696	6,034,083
5,641,882	5,770,758	6,048,824
5,643,360	5,780,469	6,057,490
5,643,774	5,783,704	6,066,596
5,645,169	5,789,214	6,071,698
5,646,145	5,792,904	6,083,881
5,646,157	5,800,997	6,091,004
5,646,288	5,804,693	6,103,667
5,648,383	5,814,453	6,107,279
5,648,487	5,814,629	6,107,544
5,650,505	5,817,502	6,117,670
5,650,517	5,817,602	6,117,892
5,654,414	5,830,899	6,130,236
5,659,124	5,831,114	6,137,033
5,662,898	5,837,290	6,147,282
5,663,176	5,840,868	D361,509
5,663,383	5,843,982	D364,956
5,670,350	5,846,571	End
5,674,514	5,847,147	
5,679,560	5,847,258	
5,679,623	5,849,870	
5,686,282	5,851,766	
5,686,283	5,852,012	
5,686,295	5,856,154	
5,686,600	5,859,300	
5,688,939	5,859,335	
5,689,044	5,859,336	
5,693,774	5,866,153	
5,698,425	5,866,326	
5,710,031	5,869,719	
5,714,599	5,872,212	
5,716,849	5,877,012	
5,721,364	5,880,328	
5,723,491	5,882,869	
5,723,721	5,883,283	
5,723,759	5,888,801	
5,728,875	5,889,174	
5,728,922	5,891,688	
5,728,923	5,912,375	